News

The company posted a net loss of $2.91m, compared to a net income of $0.32m for the same period in 2009. For the full year ended 31 December

The Phase III 48-week clinical trial evaluating the non-inferiority of Elvitegravir versus Raltegravir each administered with a background regimen in HIV-infected treatment-experienced adults with HIV RNA (viral load)

EZ-MAR is a computerized, web-based application, replaces a skilled nursing facility or institutionalized care provider’s paper records with an electronic means of maintaining medical treatment and medication administration

ARX8203 has showed positive and significant safety profile in GI toxicity studies compared with Diclofenac and Indomethacin, two very popular and currently marketed NSAIDs. AlphaRx has developed three

The drug has been approved as a treatment for endema associated with congestive heart failure, renal disease, or hepatic disease. Qualitest Pharma said the FDA’s approval for Toresmide

The company claims the jelly is a generic version of APP Pharmaceuticals’ Xylocaine. Lidocaine HCl jelly, 2% is indicated for the prevention and control of pain in procedures

The result of the study suggested that the economic model evaluated patients in Canada who were treated with Dabigatran Etexilate compared to those treated with warfarin in both

The Omega Stent System incorporates a platinum chromium (PtCr) alloy designed for coronary stenting and is intended to provide interventional cardiologists an improved acute performance in treating patients

The FDA has pointed minor observations in the company’s seven facilities in Philadelphia and five at Lannett‘s wholly owned subsidiary, Cody Laboratories, a manufacturer/supplier of pain management pharmaceutical